Recorded fact · drug.trial_access

drug.trial_access for linagliptin

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 602880f8 resolves to.

The record

Fact id	`602880f8078a0b44009e6d5f`
Entity	drug: linagliptin
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "LINAGLIPTIN",
 "recruitingInterventionalCount": 6,
 "notYetRecruitingCount": 6,
 "byPhase": {
  "PHASE4": 4,
  "PHASE3": 1,
  "NA": 1
 },
 "trials": [
  {
   "nctId": "NCT06862739",
   "briefTitle": "Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Nabiqasim Industries (Pvt) Ltd",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-04-17",
   "startDate": "2025-10-30",
   "conditions": [
    "Diabetes Mellitus",
    "Type 2 DM"
   ],
   "countries": [
    "Pakistan"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06862739"
  },
  {
   "nctId": "NCT07442006",
   "briefTitle": "Glycemic Variability of Combination Therapies in T2DM",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "JW Pharmaceutical",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-03-02",
   "startDate": "2025-10-29",
   "conditions": [
    "Type 2 Diabetes Mellitus (T2DM)"
   ],
   "countries": [
    "South Korea"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07442006"
  },
  {
   "nctId": "NCT04670666",
   "briefTitle": "Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "EMS",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2025-12-08",
   "startDate": "2024-11-18",
   "conditions": [
    "Type 2 Diabetes Mellitus"
   ],
   "countries": [
    "Brazil"
   ],
   "url": "https://clinicaltrials.gov/study/NCT04670666"
  },
  {
   "nctId": "NCT07019012",
   "briefTitle": "Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Huazhong University of Science and Technology",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2025-06-13",
   "startDate": "2025-07-30",
   "conditions": [
    "T2DM"
   ],
   "countries": [
    "China"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07019012"
  },
  {
   "nctId": "NCT06095492",
   "briefTitle": "Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus",
   "phase": [
    "NA"
   ],
   "leadSponsor": "Medanta, The Medicity, India",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2024-12-05",
   "startDate": "2023-10-30",
   "conditions": [
    "Kidney Transplant; Complications",
    "Diabetes Mellitus"
   ],
   "countries": [
    "India"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06095492"
  },
  {
   "nctId": "NCT06449833",
   "briefTitle": "Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD",
   "phase": [
    "PHASE4"
   ],
   "leadSponsor": "Zhujiang Hospital",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2024-06-10",
   "startDate": "2024-06",
   "conditions": [
    "Type2 Diabetes Mellitus",
    "Nonalcoholic Fatty Liver Disease"
   ],
   "countries": [
    "China"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06449833"
  }
 ],
 "query": {
  "intr": "linagliptin",
  "filterOverallStatus": "RECRUITING",
  "filterAdvanced": "AREA[StudyType]INTERVENTIONAL",
  "sort": "LastUpdatePostDate:desc",
  "apiVersion": "2.0.5"
 },
 "attribution": "ClinicalTrials.gov",
 "dataProcessedByRegistry": "2026-11-06T10:00:05",
 "modifications": "Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited."
}

SHA-256 of the exact stored value: 810f600686c8d22a4054125b78c7d64ff458b72474ce92bdcfe2a595afd7cda4.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.